Download PDF
Semin Thromb Hemost 2005; 31(5): 561-568
DOI: 10.1055/s-2005-922228
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Expanding Hemophilia Care in Developing Countries

Brian O'Mahony1 , Claudia Black2
  • 1Irish Haemophilia Society, Dublin Ireland
  • 2Programs Director, World Federation of Hemophilia, Montréal, Québec, Canada
Further Information

Publication History

Publication Date:
08 November 2005 (online)

    Permissions and Reprints

ABSTRACT

The World Federation of Haemophilia (WFH) estimates that worldwide, approximately 70% of patients with hemophilia are underdiagnosed and untreated. Most live in developing countries. Although in developed countries the life expectancy of hemophiliacs is close to that of healthy persons, this is not the case in developing countries. Great disparity also exists in the treatment of hemophiliacs, especially when this relates to available factor concentrates. There are many reasons for the inadequate care of hemophilic patients: the perception of rarity of the disease; lack of laboratory facilities to diagnose the disorder; lack of understanding of the disorder by patients, their relatives, and even healthcare providers; poorly developed blood bank facilities; and lack of adequate factor supply are just some examples. The WFH attempts to address many of these issues by establishing hemophilia care programs and by educating and training healthcare practitioners so that a healthcare team can be organized that attempts to ameliorate these problems and provides treatment options. In the last few years, a considerable number of developing countries have been organized to deliver at least a minimum of care, and attempts have been made to obtain support from appropriate governmental sources.

KEYWORDS

Hemophilia - World Federation of Haemophilia - educational programs - treatment centers - outreach programs

REFERENCES

  • 1 O'Mahony B. Global haemophilia care: challenges and opportunities. Lecture presented at: XXV International Congress of the WFH May 20, 2002 Seville, Spain;
    Google Scholar
  • 2 Anonymous .WFH Global Survey Data 2002. Montreal; WFH 2002
    Google Scholar
  • 3 Evatt B. Observations from Global Survey 2001: an emerging database for progress.  Haemophilia. 2002;  8 153-156
    CrossrefPubMedGoogle Scholar
  • 4 Srivastava A, Chuansumrit A, Chandy M, Duraisamy G, Karabus C. Management of haemophilia in the developing world.  Haemophilia. 1998;  4 474-480
    CrossrefPubMedGoogle Scholar
  • 5 Globe D, Cunningham W, Andersen R et al.. The Haemophilia Utilization Group Study: Cost of out-patient, in-patient and pharmaceutical care.  Int J Ped Oncol Hematol. 2001;  7 87-100
    PubMedGoogle Scholar
  • 6 Anonymous .Guidelines for the Development of a National Programme for Haemophilia, 1996. Geneva, Switzerland; WFH/WHO 1996
    Google Scholar
  • 7 Evatt B L, Robillard L. Establishing haemophilia care in developing countries: using data to overcome the barrier of pessimism.  Haemophilia. 2000;  6 131-134
    CrossrefPubMedGoogle Scholar
  • 8 Rickard K. The International Hemophilia Training Centres of the World Federation of Hemophilia: a 30-year review.  Haemophilia. 2000;  6 471-473
    CrossrefPubMedGoogle Scholar
  • 9 Anonymous .Improving Care Beyond Our Borders: A Twinning Guide for Hemophilia Treatment Centres. Montreal; WFH 2002
    Google Scholar
  • 10 Anonymous .Haemophilia in Pictures. Montreal; WFH 1996
    Google Scholar
  • 11 Anonymous .Diagnosis of Haemophilia and Other Bleeding Disorders: A Laboratory Manual. Montreal; WFH 2000
    Google Scholar
  • 12 Anonymous .Key Issues in Haemophilia Treatment. Part 1: Products. Part 2: Organizing a National Programme for Comprehensive Haemophilia Care. Monograph: Facts and Figures 1. Montreal; WFH 1998
    Google Scholar
  • 13 Lloyd S. The Preparation of Single Donor Cryoprecipitate. Monograph: Facts and Figures 2. Montreal; WFH 1997
    Google Scholar
  • 14 Petersen I P, Bird A R. Small Pool Heat Treated Intermediate Purity Factor VII Concentrate. Monograph: Facts and Figures 3. Montreal; WFH 1997
    Google Scholar
  • 15 Teitel J. Viral Safety of Coagulation Factor Concentrates. Monograph: Facts and Figures 4. Montreal; WFH 1997
    Google Scholar
  • 16 Contract Fractionation .Monograph: Facts and Figures 5. Montreal; WFH 1998
    Google Scholar
  • 17 Kasper C K, Costa e Silva M. Registry of Clotting Factor Concentrates. Monograph: Facts and Figures 6. Montreal; WFH 2000
    Google Scholar
  • 18 Teitel J. Transmissible Agents and the Safety of Coagulation Factor Concentrates. Monograph: Facts and Figures 7 (replaces #4). Montreal; WFH 1999
    Google Scholar
  • 19 Proceedings of WFH precongress symposium on Blood Component Therapy Bangkok, Thailand; October 24, 1999 Montreal; WFH
  • 20 O'Mahony B. Haemophilia Societies: Challenges and Development, WFH Monograph, January 2000. Montreal; WFH 2000
    Google Scholar
  • 21 Anonymous .Reaching Beyond Our Borders-A Twinning Guide for Haemophilia Organizations. Montreal; WFH 2001
    Google Scholar
  • 22 Isarangkura P. Haemophilia care in the developing world: benchmarking for excellence.  Haemophilia. 2002;  8 205-210
    CrossrefPubMedGoogle Scholar
  • 23 Evatt B L, Austin H, Leon G, Ruiz-Saez A, De Bosch N. Haemophilia therapy: assessing the cumulative risk of HIV exposure by cryoprecipitate.  Haemophilia. 1999;  5 295-300
    CrossrefPubMedGoogle Scholar
  • 24 . WFH/WHO recommendations, June 1997.  Haemophilia. 1998;  4(suppl 2) 64-66
    CrossrefPubMedGoogle Scholar
  • 25 Delivery of Treatment for Haemophilia. Report of a joint WHO/WFH/ISTH Meeting; February 11-13, 2002; WHO Human Genetics Programme London, United Kingdom; 2002
    Google Scholar

Brian O'Mahony Past President

WFH, Irish Haemophilia Society, Iceland House, Arran Court, Arran Quay, Dublin 7, Ireland

Email: brianihs@eircom.net

      >